BRIEF-Halozyme Reports Fourth Quarter 2020 Results
BRIEF-Halozyme Reports Fourth Quarter 2020 Results
* HALOZYME REPORTS FOURTH QUARTER 2020 RESULTS AND FULL YEAR 2020 RESULTS
* Q4 EARNINGS PER SHARE $0.50
* Q4 REVENUE $121.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $120.2 MILLION
* SEES FY 2021 GAAP EARNINGS PER SHARE $1.40 TO $1.55
* SEES FY 2021 REVENUE $375 MILLION TO $395 MILLION
* Q4 EARNINGS PER SHARE ESTIMATE $0.53 -- REFINITIV IBES DATA
* 2021 ROYALTIES PROJECTED TO DOUBLE VERSUS 2020 ROYALTIES
* PLANS TO REPURCHASE UP TO $125 MILLION IN COMMON STOCK DURING 2021 AS PART OF $550 MILLION THREE-YEAR SHARE REPURCHASE PLAN
* FY2021 EARNINGS PER SHARE VIEW $1.70, REVENUE VIEW $400.2 MILLION -- REFINITIV IBES DATA
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
Feb 23 (Reuters) - Halozyme Therapeutics Inc :
* HALOZYME REPORTS FOURTH QUARTER 2020 RESULTS AND FULL YEAR 2020 RESULTS
* Q4 EARNINGS PER SHARE $0.50
* Q4 REVENUE $121.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $120.2 MILLION
* SEES FY 2021 GAAP EARNINGS PER SHARE $1.40 TO $1.55
* SEES FY 2021 REVENUE $375 MILLION TO $395 MILLION
* Q4 EARNINGS PER SHARE ESTIMATE $0.53 -- REFINITIV IBES DATA
* 2021 ROYALTIES PROJECTED TO DOUBLE VERSUS 2020 ROYALTIES
* PLANS TO REPURCHASE UP TO $125 MILLION IN COMMON STOCK DURING 2021 AS PART OF $550 MILLION THREE-YEAR SHARE REPURCHASE PLAN
* FY2021 EARNINGS PER SHARE VIEW $1.70, REVENUE VIEW $400.2 MILLION -- REFINITIV IBES DATA
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透2月23日電-Halozyme治療公司：*Halozyme報告2020年第四季度業績和2020年全年業績*第四季度每股收益0.50美元*第四季度收入1.217億美元，而REFINITIV IBES估計為1.202億美元*預計2021財年GAAP每股收益為1.40至1.55美元*預計2021財年收入為3.75億至3.95億美元*第四季度每股收益預估0.53美元-REFINITIV IBES數據*2021年特許權使用費預計將比2020年翻一番*計劃在2021年回購最多1.25億美元的普通股，作為5.5億美元三年股票回購計劃的一部分*2021財年每股收益視圖1.70美元，收入視圖4.02億美元-REFINITIV IBES數據Eikon的源文本：進一步的公司報道：(Reurs.Briefs@thomsonreurs.com；)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧